AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03379987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PVB morphine
Description: The PVB was performed under ultrasonographic guidance in the sitting position. Surgical disinfection of thoracoabdominal paravertebral area was done. A linear high-frequency transducer (10-12 MHz, Sonosite, Bothell, WA, USA) was used. The scanning process (Longitudinal out-of-plane technique) was started at 5-10 cm lateral to the spinous process of thoracic vertebrae to identify the rounded ribs and parietal pleura underneath. The transducer is then moved progressively more medially until the transverse processes are identified as more squared structure deeper to the ribs. A 100 mm needle was inserted out-of-plane to contact the transverse process of thoracic vertebra and then, walked off above the transverse process 1-1.5 cm deeper searching for loss of resistance injecting 10 ml of 0.25% bupivacaine + 3 mg morphine for group PVB morphine in incremental doses of 3 ml.
Study NCT03379987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PVB bupivacaine
Description: the same steps mentioned in group PVB morphine but the solution used for paravertebral block contain bupivacaine only 10 ml of 0.25% bupivacaine injected in in incremental doses of 3 ml.
Study NCT02683486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intelligent oxygen therapy (an auto-titrating oxygen system)
Description: This device is an auto-titrating oxygen system. The system is programmed to maintain a specific target SpO2 by automatically adjusting the oxygen flow rate. The system can deliver flow rates of 0-5 litres/minute.
Study NCT02683486 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long-term oxygen therapy
Description: This is the patients usual long-term oxygen therapy
Study NCT03351114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crisaborole
Description: Apply Crisaborole 2% ointment to affected skin twice per day.
Study NCT05245630 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic arm assisted PET/CT guided biopsy
Description: After preparing the participant for the procedure, the participant was positioned on the PET/CT table with the immobilizer.~An automated robotic arm (MAXIO-EX, Perfint healthcare Pvt Ltd, Chennai, India) was used to guide the needle for biopsy.~Co-axial 18 G biopsy needle (BARD Biopsy disposable coaxial biopsy needle pack, Bard Peripheral Vascular, Inc., Arizona, USA) was inserted according to the orientation planned by the robotic biopsy device.~After the location is ensured, the trocar stylet is removed from the coaxial cannula and specimens were retrieved using a semiautomated biopsy gun.~A repeat CT chest was acquired two hours after the procedure to rule out post-procedural complications.~Complications during the procedure were noted, and immediate management was done.
Study NCT05245630 — intervention group
Intervention type: PROCEDURE
Intervention: PET fused CT-Fluoroscopy guided biopsy
Description: CT fluoroscopy was used to place the biopsy needle to the FDG avid lung lesion
Study NCT03833752 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic Flexible Cystosocpy
Description: Endoscopic Visualization of the Lower Urinary tract using either a flexible cystoscope for the purpose of aiding the establishment of a Urological Diagnosis.
Study NCT03833752 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic Rigid Cystoscopy
Description: Endoscopic Visualization of the Lower Urinary tract using either a rigid cystoscope for the purpose of aiding the establishment of a Urological Diagnosis.
Study NCT01942954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile health cognitive stimulation
Study NCT02455427 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: Active tDCS will be applied with the anode positioned over the ipsilesional primary motor cortex and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
Study NCT02455427 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Physical therapy will be administered for 60 minutes
Study NCT02455427 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physical Therapy
Description: Physical therapy will be administered for 60 minutes
Study NCT02455427 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: In sham tDCS, no current will be delivered through the tDCS device.
Study NCT02919748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Choral Singing
Description: Weekly sessions at 1 hour of choral singing.
Study NCT02919748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Program
Description: Weekly session at 1 hour of health education talk and group activities
Study NCT01030315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10760A or placebo
Description: Once, 0.04 mcg/kg to 2.0mcg/kg once intravenously
Study NCT02359929 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stromal cells (MSCs)
Description: Infusion of MSCs delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 1000000 cells/kg.
Study NCT03637036 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Communication intervention
Description: The intervention is a communication inviting staff to take up the influenza vaccination. Different versions of the communication are created, and the investigators will compare uptake rates between staff that received different letters.
Study NCT00987896 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colonoscopy with Megachannel™ device loaded
Description: Before colonoscopy, megachannel is loaded on the endoscope, during colonoscopy megachannel will be inserted into the patient via the endoscope placed in the colon
Study NCT04779294 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: STAN ( St wave analysis) and fetal blood sample-lactate
Description: The CTG will be analysed by an expert group additional to the standard procedure that have been done in Labour already. The STAN analysis will be decrypted/ demasked anonymously by the Company producing these machines.
Study NCT03112525 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CYP3A4/5 and P-gp phenotyping
Description: Phenotyping using a simplified version of the Geneva cocktail
Study NCT03112525 — intervention group
Intervention type: GENETIC
Intervention: CYP3A4/5 and P-gp genotyping
Description: Selected CYP3A4, CYP3A5, CYP3A7 and ABCB1 single nucleotide polymorphism (SNP) determination
Study NCT00334581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: Administration throughout the study period
Study NCT01229943 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT01229943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study NCT01229943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Acetate
Description: Given IM
Study NCT00545532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oseltamivir
Description: Dose ranging between 30 to 150 mg orally administered as syrup or capsules (depending on participant's age and weight) po twice daily for 10 days
Study NCT00545532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo matched to oseltamivir po twice daily for 10 days
Study NCT00105833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Care - Depression Decision Support (DDS)
Description: Multifaceted collaborative intervention for depression based in primary care
Study NCT03505489 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep inhalation technique
Description: Use of deep inhalations for administration of inhalant
Study NCT03505489 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tidal breathing technique
Description: Use of tidal breathing for administration of inhalant
Study NCT04202055 — intervention group
Intervention type: OTHER
Intervention: Biomarker analysis
Description: Detection of biomarker in cerebrospinal fluid
Study NCT03505489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methacholine
Description: Methacholine direct bronchoconstrictor used for bronchoprovocation challenge
Study NCT03505489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Mannitol indirect bronchoconstrictor used for bronchoprovocation challenge
Study NCT04547114 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multicapillary column coupled ion mobility spectrometry
Description: sampling of nasal air via a foam cuffed oxygen catheter
Study NCT01149486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan potassium/Hydrochlorothiazide
Description: 100/25 mg Tablets
Study NCT01149486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyzaar®
Description: 100/25 mg Tablets
Study NCT06136286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR) Cuff
Description: The intervention group will receive therapy with a blood flow restriction cuff that restricts blood flow at their individual limb occlusion pressure during specific exercises.
Study NCT00538486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan plus Metformin
Description: Telmisartan 80mg 1/d, Metformin 250mg 2/d
Study NCT04129905 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNP blood sample test
Description: Performed during normal recommended follow-up of the HCM patients.
Study NCT04129905 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: Performed during normal recommended follow-up of the HCM patients.
Study NCT04129905 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Holter ECG
Description: Performed during normal recommended follow-up of the HCM patients.
Study NCT04129905 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Performed during normal recommended follow-up of the HCM patients. Echocardiography at rest and during exercise.
Study NCT04129905 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Air venous plethysmography
Description: Performed specifically for the research. Non invasive, and non painful test evaluating different parameters of venous filling by inflation of an armband around the leg, upright positioning, flexion-extension of the leg. Total duration estimated at 30-45 minute.
Study NCT04129905 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Air venous plethysmography
Description: Performed specifically for the research. Non invasive, and non painful test evaluating different parameters of venous filling by inflation of an armband around the leg, upright positioning, flexion-extension of the leg. Total duration estimated at 30-45 minute.
Study NCT04129905 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Upper member arterial Doppler echography with analysis of FMD
Description: Performed specifically for the research. Measurement of the evolution of brachial artery diameter before and after inflation of a armband during 5 minutes. Non invasive and non painful test, duration 30 minutes.
Study NCT04129905 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Upper member arterial Doppler echography with analysis of FMD
Description: Performed specifically for the research. Measurement of the evolution of brachial artery diameter before and after inflation of a armband during 5 minutes. Non invasive and non painful test, duration 30 minutes.
Study NCT04129905 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Endothelial function biomarkers
Description: Performed specifically for the research. Blood sample test, 5 minutes.
Study NCT04129905 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endothelial function biomarkers
Description: Performed specifically for the research. Blood sample test, 5 minutes.
Study NCT05190601 — intervention group
Intervention type: DEVICE
Intervention: uroflowmetry
Description: Qmax(ml/s),Qav(ml/s),Volume (ml)
Study NCT01817101 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acid supplementation
Description: Gelatine capsule, 1 at each meals (3 per day) during one year
Study NCT02740543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate HFA 220
Description: Subjects will take two (2) puffs of Fluticasone propionate HFA 220 twice a day.
Study NCT01286987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Oral capsule with multiple dosage forms given once daily
Study NCT00004142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine
Description: Part of hepatic arterial chemotherapy on days 1-7. Treatment repeats every 5 weeks for 6 courses.
Study NCT00004142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU)
Description: Part of hepatic arterial chemotherapy over 1 hour on days 15, 22, and 29. Treatment repeats every 5 weeks for 6 courses.
Study NCT00004142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional surgery
Description: Open laparotomy to identify target tumor in liver using intraoperative ultrasound.
Study NCT00004142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Radiofrequency tissue ablation over 20 minutes to each tumor.
Study NCT03446053 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-Rephasin® SAL200
Description: continuous intravenous infusion over 60 minutes
Study NCT03446053 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: INT200-Placebo
Description: Formulation buffer except active ingredient for continuous intravenous infusion over 60 minutes
Study NCT01391598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At lidocaine group 20 pacients will receive lidocaine at a dose of 4 mg / kg, not exceeding a dose of 240 mg diluted in 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study..:Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
Study NCT01391598 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lidocaine
Description: After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At saline group 20 pacients will receive 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study. Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
Study NCT04657640 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron and folic acid (IFA)
Description: Weekly regimen of one tablet containing Iron (60mg) and Folic Acid (2800 μg) for 3 months intermittently
Study NCT04657640 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrient Supplements (MMS) and loading dose of Iron and Folic Acid (IFA)
Description: Daily regimen of MMS for 3 months intermittently. MMS is the United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) tablet containing fifteen micronutrients including iron (30mg), folic acid (400 mcg), Vit A, Retinol (800 RE), vit D (200 IU), vit E (10 mg), vit C (70 mg), vit B1 (1.4 mg), vit B2 (1.4 mg), vit B6 (1.9 mg), vit B12 (2.6 mcg), niacin (18 mg), zinc (15 mg), copper (2 mg), iodine (150 mcg), selenium (65 mcg).~For the first 5 weeks of the study, participants will also receive weekly regimen of one tablet containing Iron (60mg) and Folic Acid (2800 μg) as a loading dose, in addition to daily MMS.
Study NCT03521713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPORON
Description: * Strength : 3000 IU/0.3 mL, 5000 IU/0.5 mL, 6000IU/0.6 mL~* Formulation : Solution in PFS
Study NCT03521713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPREX
Description: * Strength : 2000 IU/0.3 mL, 3000 IU/0.5 mL, 4000IU/0.6 mL~* Formulation : Solution in PFS
Study NCT00538486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Telmisartan 80mg 1/d
Study NCT00538486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: Candesartan 8mg daily
Study NCT00538486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan plus Metformin
Description: Candesartan 8mg 1/d Metformin 250mg 2/d
Study NCT00538486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5mg 1/d
Study NCT00538486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine plus Metformin
Description: Amlodipine 5mg 1/d, Metformin 250mg 2/d
Study NCT06178835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: 500 IU/kg of erythropoietin is given 3 times for each patient: the day before surgery, start of surgery and on postoperative day 1.
Study NCT06178835 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: The same amount of normal saline is given 3 times for each patient: the day before surgery, start of surgery and on postoperative day 1.
Study NCT01462851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05297909 25 mg
Description: Single oral (PO) dose, PF-05297909 25 mg
Study NCT01462851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05297909 100 mg
Description: Single oral (PO) dose, PF-05297909 100 mg
Study NCT01462851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05297909 250 mg
Description: Single oral (PO) dose, PF-05297909 250 mg
Study NCT01462851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05297909 525 mg
Description: Single oral (PO) dose, PF-05297909 525 mg
Study NCT01462851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05297909 525 mg
Description: Single oral (PO) dose, 525 mg
Study NCT03586076 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JHL1922
Description: Single doses of JHL1922 2.5 mg and then 10 mg per eRapid nebulizer
Study NCT03586076 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: dornase alfa
Description: Single doses of Pulmozyme® 2.5 mg and then 10 mg per eRapid nebulizer
Study NCT04651647 — intervention group
Intervention type: PROCEDURE
Intervention: Revision surgery with / without open bone graft
Description: Removal of previous implant and re-alignment and re-fixation using intramedullary nail with (bone graft group) / without (non bone graft group) open bone graft
Study NCT02356042 — intervention group
Intervention type: OTHER
Intervention: Geriatric inclusive art (GIA) activity
Description: The frequency of GIA sessions in this study was from 1 to 2 per month. The time of a session was around 1 hour 30 minutes. Participants of intervention group benefited GIA activity during a 6-month follow-up period.
Study NCT03607994 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HIRREM-SOP
Description: HIRREM-SOP is an updated version of HIRREM. It is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.
Study NCT03607994 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HIRREM-SOP
Description: HIRREM-SOP is an updated version of HIRREM. It is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.
Study NCT03607994 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NCC
Description: Nonspecific acoustic stimulation with randomly generated tones not linked to brain activity.
Study NCT02358928 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet Intervention
Study NCT01031940 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: macintosh laryngoscope
Description: intubate with the macintosh laryngoscope
Study NCT01031940 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-MAC laryngoscope
Description: intubate with the C-MAC laryngoscope
Study NCT01084811 — intervention group
Intervention type: PROCEDURE
Intervention: biopsy
Description: One or more biopsies from nasal mucosa will be harvested during surgery
Study NCT04322058 — intervention group
Intervention type: OTHER
Intervention: The Dads' Club
Description: The core intervention is Core 24/7 workshop attendance
Study NCT03508193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional therapy
Description: Whole-foods based smoothie designed to emulate formulas used in EEN
Study NCT03043495 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided supraclavicular brachial plexus block
Description: ultrasound guided Supraclavicular brachial plexus block
Study NCT03043495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Various doses of Dexamethasone (2, 4 \& 8 mg) to be used as an Adjuvant to Local anesthetic drugs